The effect of vaccination against the COVID-19 on the course and outcomes of a new coronavirus infection: a retrospective analysis of laboratory and clinical indicators of hospitalized patients

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

BACKGROUND: The Gam-COVID-Vac vaccine was proven effective in preventing the severe course and adverse outcomes of COVID-19 during different periods of the pandemic. However, the effect of vaccination on laboratory marker levels in hospitalized patients during the spread of the omicron variant of SARS-CoV-2 has not been sufficiently studied.

AIM: To assess the effect of vaccination on the severity and outcomes of COVID-19 in hospitalized patients during the dominance of the SARS-CoV-2 omicron variant in Russia.

MATERIALS AND METHODS: This case–control study included adult patients diagnosed with COVID-19 (U07.1) and hospitalized in infectious hospitals in Moscow between February 1, 2022, and July 31, 2022 (n=119). The main group included individuals vaccinated with two doses of Sputnik V vaccine (n=59). The control group included individuals who were not vaccinated (n=60). The median patient age was 66 [interquartile range, 41–66] years, and 58.8% were female. The chi-square test for categorical variables and the Mann–Whitney test for continuous variables were used for the analysis. P-values <0.05 were considered statistically significant.

RESULTS: Viral pneumonia was less likely to develop in the vaccinated group than in the unvaccinated group (46.7% and 18.6%, respectively, p = 0.007). The proportion of patients without lung damage (0 CT-severity scores) in the vaccinated group (72.0%) was significantly higher than that in the unvaccinated group (42.9%) (p=0.003). In the vaccinated group, the levels of C-reactive protein on admission were lower (29.1 [7.4–68.6] mg/L and 75.1 [32.4–104.0] mg/L, p <0.001), and the highest level was recorded during hospitalization (38.2 [12.0–84.0] mg/L and 92.2 [45.3–137.4] mg/L, p <0.001). The D-dimer levels before discharge were lower in the group of patients vaccinated <6 months ago than in the unvaccinated group (157.0 [107.0–297.0] ng/mL and 316.0 [125.0–556.0] ng/mL, respectively, p = 0.014). The frequency of deaths in the control group (11.7%) was 6.9 times higher than that in the main group (1.7%) (p = 0.030).

CONCLUSIONS: Completion of the primary vaccination course of Sputnik V vaccine resulted in lower levels of prognostic markers of severe COVID-19 (C-reactive protein and D-dimer) and a decrease in the frequency of pulmonary and fatal outcomes than in the unvaccinated group during the dominance of the omicron variant of SARS-CoV-2.

作者简介

Anastasia Fomicheva

I.M. Sechenov First Moscow State Medical University (Sechenov University)

编辑信件的主要联系方式.
Email: anastasia.fomichova@yandex.ru
ORCID iD: 0000-0002-0625-0284
SPIN 代码: 5281-1670

MD

俄罗斯联邦, 8 Trubetskaya street, 119048 Moscow

Nikolay Pimenov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: n.pimenov@mail.ru
ORCID iD: 0000-0002-6138-4330
SPIN 代码: 2314-2076

MD, Cand. Sci. (Med.)

俄罗斯联邦, 8 Trubetskaya street, 119048 Moscow

Anna Tsygankova

I.M. Sechenov First Moscow State Medical University (Sechenov University); Infectious Diseases Clinical Hospital No. 2

Email: anna.tsygankova.inf@gmail.com
ORCID iD: 0000-0003-3766-1868
SPIN 代码: 6583-0476

MD

俄罗斯联邦, 8 Trubetskaya street, 119048 Moscow; 28/4-1 Volnaya street, 105187 Moscow

Natalia Tsapkova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: tsapkova.natali@yandex.ru
ORCID iD: 0000-0002-7823-9287
SPIN 代码: 3734-7392

MD, Cand. Sci. (Med.), Associate Professor

俄罗斯联邦, 8 Trubetskaya street, 119048 Moscow

Darya Rokhlina

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: rokhlina_d_a@staff.sechenov.ru

MD

俄罗斯联邦, 8 Trubetskaya street, 119048 Moscow

Elena Volchkova

I.M. Sechenov First Moscow State Medical University (Sechenov University); Infectious Diseases Clinical Hospital No. 2

Email: antononina@rambler.ru
ORCID iD: 0000-0003-4581-4510
SPIN 代码: 3342-4681

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 8 Trubetskaya street, 119048 Moscow; 28/4-1 Volnaya street, 105187 Moscow

Svetlana Krasnova

Infectious Diseases Clinical Hospital No. 2

Email: krasnovasv@ikb2.ru
ORCID iD: 0000-0001-8592-5624
SPIN 代码: 3652-3811

MD, Cand. Sci. (Med.)

俄罗斯联邦, 28/4-1 Volnaya street, 105187 Moscow

Vladimir Chulanov

I.M. Sechenov First Moscow State Medical University (Sechenov University); National Medical Research Center of Phthisiopulmonology and Infectious Diseases; Sirius University of Science and Technology

Email: vladimir@chulanov.ru
ORCID iD: 0000-0001-6303-9293
SPIN 代码: 2336-4545

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, 8/2 Trubetskaya street, 119048 Moscow; 4/1, Dostoevsky st. , 127473 Moscow; Sochi

参考

  1. Weekly epidemiological update on COVID-19 — 4 January 2023. World Health Organization [Internet]. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---4-january-2023.
  2. Stopcoronavirus.rf [Internet]. (In Russ). Available at: https://стопкоронавирус.рф.
  3. Tiruneh SA, Tesema ZT, Azanaw MM, Angaw DA. The effect of age on the incidence of COVID-19 complications: A systematic review and meta-analysis. Syst Rev. 2021;10(1):80. doi: 10.1186/s13643-021-01636-2
  4. Pellicori P, Doolub G, Wong CM, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev. 2021;3(3):CD013879. doi: 10.1002/14651858.CD013879
  5. Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021;76(10):970–979. doi: 10.1136/thoraxjnl-2020-215383
  6. Sahranavard M, Akhavan Rezayat A, Zamiri Bidary M, et al. Cardiac Complications in COVID-19: A Systematic Review and Meta-analysis. Arch Iran Med. 2021;24(2):152–163. doi: 10.34172/aim.2021.24
  7. Zhao YH, Zhao L, Yang XC, Wang P. Cardiovascular complications of SARS-CoV-2 infection (COVID-19): A systematic review and meta-analysis. Rev Cardiovasc Med. 2021;22(1):159–165. doi: 10.31083/j.rcm.2021.01.238
  8. Raina R, Mahajan ZA, Vasistha P, et al. Incidence and Outcomes of Acute Kidney Injury in COVID-19: A Systematic Review. Blood Purif. 2022;51(3):199–212. doi: 10.1159/000514940
  9. Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021;26(3):107–108. doi: 10.1136/bmjebm-2020-111536
  10. Wang L, Yang LM, Pei SF, et al. CRP, SAA, LDH, and DD predict poor prognosis of coronavirus disease (COVID-19): a meta-analysis from 7739 patients. Scand J Clin Lab Invest. 2021;81(8):679–686. doi: 10.1080/00365513.2021.2000635
  11. Matthay MA, Arabi Y, Arroliga AC, et al. A New Global Definition of Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine. 2024;209(1):37–47. doi: 10.1164/rccm.202303-0558WS
  12. Crimi C, Murphy P, Patout M, Sayas J, Winck JC. Lessons from COVID-19 in the management of acute respiratory failure. Breathe (Sheff). 2023;19(1):230035. doi: 10.1183/20734735.0035-2023
  13. Zheng C, Shao W, Chen X, et al. Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis. Int J Infect Dis. 2021;114:252–260. doi: 10.1016/j.ijid.2021.11.009
  14. Patel AK, Patel D, Shevkani M, et al. COVID-19 patients’ clinical profile and outcome with respect to their vaccination status: A prospective observational multicentre cohort study during third wave in Western India. Indian J Med Microbiol. 2023;41:28–32. doi: 10.1016/j.ijmmb.2022.12.004
  15. Fatima S, Zafar A, Afzal H, et al. COVID-19 infection among vaccinated and unvaccinated: Does it make any difference? PloS one. 2022;17(7):e0270485. doi: 10.1371/journal.pone.0270485
  16. Barchuk A, Bulina A, Cherkashin M, et al. Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg: A test-negative case-control study. Respir Res. 2022;23(1):276. doi: 10.1186/s12931-022-02206-3
  17. Shkoda AS, Gushchin VA, Ogarkova DA, et al. Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. Vaccines (Basel). 2022;10(6):938. doi: 10.3390/vaccines10060938
  18. Wang J, Choy KW, Lim HY, Ho P. Impaired Fibrinolytic Potential Predicts Oxygen Requirement in COVID-19. J Pers Med. 2022;12(10):1711. doi: 10.3390/jpm12101711
  19. Feldblum IV, Repin TM, Devyatkov MY, et al. Preventive Efficacy of Domestic Vaccines against a New Coronavirus Infection in the Immunization of Employees of Medical Organizations. Epidemiology and Vaccinal Prevention. 2023;22(1):22–27. (In Russ). doi: 10.31631/2073-3046-2023-22-1-22-27
  20. Nikonov EL, Boychenko YuYa, Kuznetsova AV. Effectiveness of Gam-COVID-Vac vaccine in the Khabarovsk region from october 2020 to june 2021 based on registers data. Profilakticheskaya Meditsina. 2021;24(11):62–69. (In Russ). doi: 10.17116/profmed20212411162
  21. Molchanova ZhR, Babura EA, Zaguzov VS, Lyalina LV. COVID-19 Epidemic in the Kaliningrad Region: Incidence and Infection Control Measures. Public Health and Life Environment — PH&LE. 2023;31(3): 52–63. (In Russ). doi: 10.35627/2219-5238/2023-31-3-52-63
  22. Poteshkina NG, Krylova NS, Ibragimova AM, et al. Respiratory and thromboembolic complications of COVID-19-associated pneumonia in COVID-19 vaccinated patients. Lechebnoe delo. 2023;(2):81–86. (In Russ). doi: 10.24412/2071-5315-2023-12883
  23. Linets YuP, Artyukhov SV, Kazantsev AN, et al. COVID-19 Course in Vaccinated Patients. Russian Sklifosovsky Journal “Emergency Medical Care”. 2021;10(4):636–641. (In Russ). doi: 10.23934/2223-9022-2021-10-4-636-641
  24. Moiseeva AG, Serova NYu, Shaikhutdinova RA, et al. Thrombosis in unvaccinated and Gam-COVID-Vac-vaccinated patients with COVID-19. Russian Journal of Cardiology. 2022;27(7):5091. (In Russ). doi: 10.15829/1560-4071-2022-5091
  25. Kostinov MP, Zhang C, Khrapunova IA, et al. Time-dependent changes of platelet and D-dimer parameters in vaccinated versus non-immunized COVID-19 patients. Russian Journal of Immunology. 2023;26(4):627–632. doi: 10.46235/1028-7221-13983-TDC
  26. Tracking of hCoV-19 Variants. GISAID [Internet]. Available at: https://gisaid.org/hcov19-variants/.
  27. Khare S, Gurry C, Freitas L, et al. GISAID’s Role in Pandemic Response. China CDC Weekly. 2021;3(49):1049–1051. doi: 10.46234/ccdcw2021.255
  28. Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: A systematic review and meta-analysis. BMC Med. 2022;20:200. doi: 10.1186/s12916-022-02397-y
  29. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376:e069761. doi: 10.1136/bmj-2021-069761
  30. Zizza A, Sedile R, Bagordo F, et al. Factors Associated with Pneumonia in Patients Hospitalized with COVID-19 and the Role of Vaccination. Vaccines. 2023;11(8):1342. doi: 10.3390/vaccines11081342

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Severity of lung changes according to the results of computed tomography (CT) among vaccinated and unvaccinated patients with COVID-19. * A proportion of patients with 0 CT-severity scores was significantly higher in the main group (Chi-Square test, p <0.05). **A total proportion of patients with 1–4 CT-severity scores was significantly lower in the main group (Chi-Square test, p <0.05).

下载 (656KB)
索引源数据

版权所有 © Eco-vector, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


##common.cookie##